Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 4, 2008, Pages 297-305

  Page, Andrea V ^a,b,c   Liles, W Conrad ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Aspergillosis; Candidiasis; Mucormycosis; Posaconazole; Zygomycosis

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CYCLOSPORIN; ERGOT ALKALOID; FLUCONAZOLE; ITRACONAZOLE; MIDAZOLAM; PHENYTOIN; POSACONAZOLE; RIFABUTIN; TACROLIMUS; VORICONAZOLE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; CHOLESTASIS; CHROMOMYCOSIS; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; ESOPHAGUS CANDIDIASIS; EUMYCETOMA; EXPERIMENTAL MODEL; FATIGUE; FETUS MALFORMATION; FUNGICIDAL ACTIVITY; HEADACHE; HISTOPLASMOSIS; HUMAN; LIVER FAILURE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUCORMYCOSIS; MULTIPLE CYCLE TREATMENT; MYCETOMA; NAUSEA; NONHUMAN; OROPHARYNX CANDIDIASIS; PHAEOHYPHOMYCOSIS; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SKELETON MALFORMATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 57149104226     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/825901     Document Type: Review

References (75)

1. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16.
2. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161-70.
3. Ullmann AJ, Sanz MA, Tramarin A, et al; Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006;43:e29-38.
4. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: An emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004;101:1594-600.
5. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39:425-9.
6. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020.
7. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007;51:1876-8.
8. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57:705-8.
9. Baixench MT, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: Case report and review. J Antimicrob Chemother 2007;59:1076-83.
10. Schering-Plough Canada Inc. Spriafil (posaconazole) product monograph, 2007.
11. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. 〈http://www.emea.europa.eu/htms/human/epar/eparintro. htm〉 (Version current at June 5, 2008).
12. Munayyer HK, Mann PA, Chau AS, et al. Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004;48:3690-6.
13. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95.
14. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22.
15. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20.
16. Pfizer Canada Inc. Vfend (voriconazole) product monograph, 2006.
17. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
18. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47. (Erratum in 2007;357:428).
19. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007;44:2-12.
20. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51.
21. Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996;40:1910-3.
22. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004;48:4063-6. (Erratum in 2004;48:4931).
23. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55.
24. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
25. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-92.
26. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502.
27. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51:812-8.
28. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-44.
29. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34.
30. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53.
31. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15.
32. Sóczó G, Kardos G, McNicholas PM, et al. Correlation of posaconazole minimum fungicidal concentration and time-kill test against nine Candida species. J Antimicrob Chemother 2007;60:1004-9.
33. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JF, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002;46:1144-6.
34. Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997;41:1558-61.
35. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
36. Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996;40:1314-6.
37. Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001;39:4208-9.
38. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-5.
39. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6.
40. Groll AH, Walsh TJ. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006;49(Suppl 1):7-16.
41. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-86.
42. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44:607-14.
43. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group study 323/Mycoses Study Group study 40. Clin Infect Dis 2005;41:1473-80.
44. Barchiesi F, Maracci M, Radi B, et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002;50:999-1002.
45. Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA. Second-line therapy with caspofungin for mucosal or invasive candidiasis: Results from the caspofungin compassionate-use study. J Antimicrob Chemother 2004;53:878-81.
46. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007;8:86-97.
47. Vehreschild JJ, Krüger K, Kurzai O, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 2006;49(Suppl 1):42-7.
48. Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. Med Mycol 2008;46:79-83.
49. Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008;22:496-503.
50. Maertens J, Glasmacher A, Herbrecht R, et al; Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006;107:2888-97.
51. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007;9:89-96.
52. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5. (Erratum in 2006;43:1376).
53. Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007;45:562-8.
54. Walsh TJ, Anaissie EJ, Denning DW, et al; Infectious Diseases Society of America. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
55. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004;48:568-74.
56. Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004;53:74-80.
57. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004;48:2124-31.
58. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH 56592). J Antimicrob Chemother 2000;46:229-34.
59. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother 2005;49:3544-5.
60. Barchiesi F, Schimizzi AM, Caselli F, et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2435-41.
61. Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 2005;49:638-42.
62. Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 2006;50:2587-90.
63. Keating GM. Posaconazole. Drugs 2005;65:1553-67.
64. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007;55:287-99.
65. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004;42:4419-31.
66. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007;27:369-88.
67. Revankar SG. Dematiaceous fungi. Mycosis 2007;50:91-101.
68. Greenberg RN, Mullane K, van Burik JH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.
69. Negroni R, Helou SH, Petri N, Robles AM, Arechavala A, Bianchi MH. Case study: Posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004;38:e15-20.
70. Proia LA, Trenholme GM. Chronic refractory phaeohyphomycosis: Successful treatment with posaconazole. Mycoses 2006;49:519-22.
71. Negroni R, Tobón A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005;47:339-46.
72. Restrepo A, Tobón A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007;54:319-27.
73. Stevens DA, Rendon A, Gaona-Flores V et al. Posaconazole therapy for refractory coccidioidomycosis. Chest 2007;132:952-8.
74. Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001;20:460-6.
75. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.